Thermo Fisher Scientific Announces Major Biopharma Investments in Hyderabad’s Genome Valley
With this investment, Thermo Fisher is positioning itself as a long-term partner in India’s biopharma journey, reinforcing the country’s ambition to emerge as a global leader in life sciences innovation and supply chains.
Hyderabad, August 22: Thermo Fisher Scientific has announced significant investments in India’s biopharma ecosystem, unveiling plans to set up state-of-the-art facilities at Genome Valley in Hyderabad. The announcement was made during the Biopharma Conclave 2025 held in Hyderabad this week, highlighting the company’s commitment to strengthening India’s role as a global hub for biopharmaceutical innovation and manufacturing.
The new facilities are expected to enhance capabilities in drug development, clinical research, and advanced manufacturing, offering end-to-end solutions to both domestic and international biopharma companies. Genome Valley, already recognized as India’s largest cluster for life sciences research and manufacturing, will serve as a strategic base for Thermo Fisher’s expanded operations.
Speaking at the conclave, senior Thermo Fisher executives underscored India’s growing importance in the global healthcare landscape. They emphasized that the investments would not only bolster innovation but also create high-value employment opportunities for scientists, researchers, and skilled professionals in the country.
Industry observers note that the move comes at a crucial time when India is striving to deepen its capabilities in biopharmaceuticals, especially in the areas of vaccines, biosimilars, and precision medicine. Thermo Fisher’s expansion is expected to complement government initiatives aimed at advancing research and development, strengthening manufacturing capacity, and fostering global partnerships in the healthcare sector.
The company said the upcoming Genome Valley facilities will integrate cutting-edge technologies to accelerate drug discovery and streamline production, ultimately supporting faster delivery of affordable therapies to patients worldwide.
With this investment, Thermo Fisher is positioning itself as a long-term partner in India’s biopharma journey, reinforcing the country’s ambition to emerge as a global leader in life sciences innovation and supply chains.
